Ryan Haumschild, PharmD, MS, MBA, CPEL

Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology (ASH) Annual Meeting and Exposition, highlighting emerging data that may refine their use in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), particularly in optimizing treatment duration and sequencing to improve patient outcomes.

Panelists discuss how patient-reported outcomes and real-world evidence influence clinical decision-making when selecting Bruton tyrosine kinase (BTK) inhibitors for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL).

Panelists discuss how biosimilar adoption requires multifaceted organizational readiness, involving strategic infrastructure reconfiguration, comprehensive stakeholder education, rigorous clinical and economic evaluation frameworks, and adaptable operational processes to ensure seamless integration and optimization of health care delivery.

Panelists discuss how private label agreements facilitate biosimilar market entry by allowing manufacturers to collaborate on branding, distribution, and market access, ultimately expanding treatment options and potentially reducing health care costs.

Panelists share their final thoughts on bispecific therapies in B-cell lymphomas based on insights from the 66th American Society of Hematology (ASH) Annual Meeting and Exposition 2024.

Panelists discuss the treatment- and patient-specific factors considered when determining induction therapy for treatment-naive patients with mantle cell lymphoma (MCL), including the decision between aggressive and less aggressive approaches, and how prior therapy exposure influences subsequent treatment sequencing for MCL.

Panelists discuss key gaps in communication between academic and community centers regarding the use of bispecifics and strategies to bridge them as well as best practices for ensuring a smooth transition of care when patients move between settings.

Panelists provide an overview of the current landscape of induction therapies for mantle cell lymphoma (MCL), discussing the role of Bruton tyrosine kinase (BTK) inhibitors in this setting and the use of aggressive induction therapies.

Panelists discuss how employers optimize biosimilar uptake through strategic formulary design, financial incentives, and provider education, enabling health care systems to achieve substantial cost savings while maintaining high-quality patient care.

Panelists discuss how biosimilars have significantly reduced health care costs in the US, with health care systems experiencing significant savings across various therapeutic areas. These cost reductions improve treatment affordability and patient access, with potential cumulative savings in 2025.

Panelists discuss how therapy sequencing is approached for patients with chronic lymphocytic leukemia (CLL), with a focus on how prior therapy exposure influences the choice of subsequent treatments.

Panelists discuss the benefits of implementing bispecific therapy programs in the community setting as well as factors influencing the decision to administer these agents at an academic center vs a community setting.

Panelists discuss the factors considered when selecting between BTK inhibitors and venetoclax plus obinutuzumab for chronic lymphocytic leukemia (CLL), the considerations for choosing among acalabrutinib, zanubrutinib, and ibrutinib, and the role of cytotoxic chemotherapy in the treatment of CLL in the era of targeted therapies.

Panelists discuss best practices for successfully implementing a bispecifics program and overcoming logistical challenges.

Panelists discuss the most common logistical challenges encountered when implementing bispecific therapies in both academic and community settings.

Panelists provide an overview of the current first-line treatment options for chronic lymphocytic leukemia (CLL), discussing the role of BTK inhibitors and venetoclax plus obinutuzumab (CLL14), and explore the continued role of ibrutinib in the CLL treatment landscape.

Panelists discuss how step-up dosing protocols reduce cytokine release syndrome (CRS) risk in patients with high-risk disease and when modifications might be necessary as well as the incorporation of infection prevention strategies, including prophylactic antimicrobials, into management plans.

Panelists discuss key strategies for preventing cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) in patients receiving bispecific therapies for B-cell lymphomas.

Panelists discuss how challenges in implementing emerging Bruton tyrosine kinase inhibitor (BTKi) regimens for treatment-naive patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) may include issues related to access, cost, and patient adherence, and highlight the need for ongoing research and collaboration to optimize BTKi use and improve patient outcomes in both diseases.

Panelists discuss how real-world data on the incidence of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) compare with clinical trial findings as well as the most critical patient-related risk factors for developing these toxicities.

Panelists discuss how comparative data from matching-adjusted indirect comparison (MAIC) analyses guide treatment decisions between bispecific therapies and the insights from MAIC results comparing epcoritamab and glofitamab that may influence therapy selection.

Panelists discuss key factors in deciding between monotherapy and combination approaches for bispecific therapies in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) as well as the potential for combination therapies to be more viable in certain B-cell lymphoma subtypes.

Panelists discuss how the clinical implications of emerging Bruton tyrosine kinase inhibitor (BTKi)trials in mantle cell lymphoma (MCL) are addressing unmet needs by providing novel therapeutic options, and explore how the integration of these therapies into current chronic lymphocytic leukemia (CLL) and MCL treatment guidelines could reshape management strategies, with consideration given to factors such as efficacy, safety, and patient access.

Panelists discuss how the sequencing of bispecific therapies in first-line vs later-line settings should be guided by factors such as disease stage, prior treatments, and patient-specific characteristics to optimize therapeutic outcomes.

Panelists discuss how several studies evaluating bispecific therapies in earlier lines of therapy for diffuse large B-cell lymphoma and follicular lymphoma suggest that patients with high-risk or relapsed/refractory disease are most likely to benefit from these treatments.

Panelists discuss how emerging Bruton tyrosine kinase inhibitor (BTKi) treatment regimens for treatment-naive patients with mantle cell lymphoma (MCL), including acalabrutinib + bendamustine + rituximab (ECHO), acalabrutinib + lenalidomide + rituximab (ALR), acalabrutinib + umbralisib + ublituximab (AU2), ibrutinib + rituximab (ENRICH), and zanubrutinib + rituximab (CHESS), are exploring novel combinations to improve treatment outcomes and address unmet clinical needs in MCL therapy.

Panelists discuss how emerging data on odronextamab in diffuse large B-cell lymphoma suggest its potential to play a significant role in therapy, with promising results that may position it alongside or as a superior option compared with currently approved bispecifics.

Panelists discuss how the clinical implications of emerging Bruton tyrosine kinase inhibitor (BTKi) trials in chronic lymphocytic leukemia (CLL) are addressing unmet needs by offering new treatment options that target treatment-naive patients, potentially improving outcomes and filling gaps in the current therapeutic landscape.

A panelist discusses how biosimilar adoption faces multiple barriers despite proven cost benefits, exploring strategies for improving uptake, best practices for interchangeability, experiences with adalimumab switching, and future optimization opportunities in healthcare systems.